ERNAW

distress 3/10 · well-funded / low risk

$0.07-3%today-38% from 52w high

ernexatx.com5 employeesFounded 2018Cambridge, MA

Revenue

pre-revenue

Liquidity

$9M

Runway

1.3 yrs

Shares 1y

-85%

Price & events

+9.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-3.0%

-38.2%

—

+9.7%

All

Overview

Market Cap: $79.31K
Volume: 2.13K
52 Week Range: $0.04 – $0.11
Total Shares: 1.17M
Float Shares: 668.72K
RVOL: 0.41x
Beta: 2.51

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 0

No catalyst news yet.

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,166,333 · 1 offerings/1y · 0 PIPEs

2026-03-30EFFECTshelf_effective
2026-03-24S-3/Ashelf_registration
2026-03-16S-3shelf_registration
2026-02-118-Kmaterial_agreement
2026-02-10424B5offering
2026-02-05S-1/Ashelf_registration
2026-02-05EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified